Company Information
CIN
Status
Date of Incorporation
15 May 1995
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
11 August 2023
Paid Up Capital
1,012,200,000
Authorised Capital
1,725,000,000
Directors
Monappa Arun Akhil
Director/Designated Partner
over 2 years ago
over 2 years ago
Dharmishta Narendraprasad Raval
Director/Designated Partner
over 2 years ago
over 2 years ago
Bhadresh Kantilal Shah
Director/Designated Partner
over 2 years ago
over 2 years ago
Nitinkumar D Parekh
Director/Designated Partner
over 2 years ago
over 2 years ago
Vishal Jyotindra Gor
Director/Designated Partner
over 2 years ago
over 2 years ago
Nitin Raojibhai Desai
Director/Designated Partner
over 2 years ago
over 2 years ago
Sharvil Pankajbhai Patel
Director/Designated Partner
over 2 years ago
over 2 years ago
Upasana Konidela
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Pritiben Pankajbhai Patel
Beneficial Owner
over 6 years ago
over 6 years ago
Pankaj Ramanbhai Patel
Director/Designated Partner
over 8 years ago
over 8 years ago
Ganesh Narayan Nayak
Director/Designated Partner
over 8 years ago
over 8 years ago
Mukesh Mangalbhai Patel
Director/Designated Partner
over 28 years ago
over 28 years ago
Past Directors
Apurva Shishir Diwanji
Additional Director
over 9 years ago
over 9 years ago
Humayun Dhanrajgir
Director
over 22 years ago
over 22 years ago
Upenkumar Harshadlal Shah
Company Secretary
almost 23 years ago
almost 23 years ago
Pranlal Bhogilal Patel
Director
almost 27 years ago
almost 27 years ago
Patents
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. Th...
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparati...
The present invention relates to Fc variant protein and preparation thereof. Said Fc variant has altered binding affinity towards FcRn. Fc variant prepared according to the current invention can be used for making FcRn antagonist composition or can be used for making an Fc variant containing drug or molecule with al...
The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions ...
Present invention describes synergistic composition comprising compound of formula (I) and at least one additional therapeutic agents such as ezetimibe, eicosapentaenoic acid, nicotinic acid derivatives and bempedoic acid derivatives, salt thereof. Invention also describes use of synergistic composition for the trea...
The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide o...
The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present...
Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical compositio...
The present invention relates to novel pharmaceutically acceptable salts of formula (Ia). The invention is also related to process for the preparation of the said novel salts and pharmaceutical composition of the same. Compounds of the present invention are prolyl hydroxylase inhibitors and are suitable for the trea...
The present invention relates to novel heterocyclic compounds of general formula (I) and their pharmaceutically acceptable salts, enantiomers and their diastereomers that are autotaxin (ATX) inhibitors. Compounds of general formula (I), their pharmaceutically acceptable salts and pharmaceutical composition are usefu...
The present invention generally relates to a pharmaceutical composition of suitable HIF prolyl hydroxylase inhibitors. Preferably, the present invention discloses novel formulations of the compound of formula (Ia), or pharmaceutically acceptable salts of compounds of formula (Ia). More particularly the present inven...
The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.
ABSTRACT
“IMPROVED PROCESS FOR THE PREPARATION OF (R)-1-(TERT-BUTOXYCARBONYL)-2-METHYLPYRROLIDINE-2-CARBOXYLIC ACID”
Present invention provides an improved process for the preparation of (R)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid of formula (I).
ABSTRACT
“Improved process for the preparation of Nirmatrelvir”
Present invention relates to an improved process for the preparation of Nirmatrelvir. The present invention also relates to a novel amorphous form of the Nirmatrelvir and process for the preparation thereof. The invention also relates to pharmaceuti...
Present invention relates to development of compound of formula (Ia) for treatment of inflammatory bowel diseases. Invention also relates to pharmaceutical composition comprising therapeutically effective compound of formula (Ia) for treatment of inflammatory bowel diseases.
ABSTRACT
"NOVEL NLRP3 INFLAMMASOME INHIBITORS"
The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, deuterated analogs, metabolites, diastereomers and polymorphs. The compounds are novel NLRP3 modu...
"Peptide(s) with protease activity and its use for the treatment or prevention of coronavirus infection"
Abstract
The present invention provides a composition comprising peptide(s) with protease activity. The composition according to the present invention is used for pharmaceutical purpose. It can also be used...
ABSTRACT
“NOVEL POLYMORPHIC FORMS OF QUINOLONE BASED COMPOUNDS”
The present invention relates to novel crystalline forms of quinolone based compounds and process for the preparation thereof, use thereof and pharmaceutical composition comprising the same.
ABSTRACT
PROCESS FOR THE PREPARATION OF VOXELOTOR
The present invention relates to a process for preparation of Voxelotor of Formula (I). The present invention also relates to a process for preparing intermediate useful in the preparation of Voxelotor.
...
A pharmaceutical formulation of anti-interleukin-5 antibody and preparation thereof
Abstract
The present invention provides a pharmaceutical formulation of anti-interleukin-5 (anti-IL-5) antibody, preferably mepolizumab. In one aspect, the pharmaceutical formulation of the present invention comprises therapeut...
ABSTRACT
PROCESS FOR THE PREPARATION OF VILOXAZINE HYDROCHLORIDE
The present invention relates to a process for preparation of Viloxazine hydrochloride. The present invention also relates to a process for preparing intermediates useful in the preparation of viloxazine hydrochloride.
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE RELUGOLIX
The present invention relates to an improved process for the preparation of Relugolix, compound of Formula (I), substantially free from impurities. In particular, the invention relates to an improved process for the preparation of high purity ...
ABSTRACT
“STABLE PHARMACEUTICAL COMPOSITIONS OF CALCIUM POLYSTYRENE SULFONATE”
The present invention relates to provide a stable oral suspension of calcium polystyrene sulfonate. Further, present invention is also provides a process of preparation of a stable oral suspension of calcium polystyrene sulfonate. A sta...
ABSTRACT
A pharmaceutical formulation of daratumumab antibody with suitable excipients
The present invention provides a pharmaceutical formulation of daratumumab antibody with suitable pharmaceutical excipient(s). In one aspect, the pharmaceutical formulation of the present invention comprises therapeutically effe...
Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Invention also ...
Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical composition of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or it...
ABSTRACT
“PROCESS FOR THE PREPARATION OF QUINOLONE BASED COMPOUNDS”
The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation ...
This invention relates to a field of pharmaceuticals, in particular to desidustat particles having specific particle size distribution and pharmaceutical compositions thereof.
ABSTRACT
A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE
COMPOUND AND INTERMEDIATES THEREOF
The present invention relates to crystalline triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. Th...
The present invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and optionally one...
The present invention relates to the development of therapeutic compound for the treatment of brain psychiatric diseases. Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt or suitable composition useful in the treatment of neuroinflammatory disorders or neurodege...
The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.
The invention relates to an amorphous solid dispersion of a quinolone compound of Formula I and process for the preparation thereof.
ABSTRACT
“PROCESS FOR OBTAINING PURE POLYMORPHIC FORMS OF QUINOLONE BASED COMPOUND”
The present invention relates to a process for obtaining pure polymorphic form I of quinolone based compound of formula (I). The present invention also relates to process for obtaining pure polymorphic form II of formula (I).
...
IMPROVED PROCESS FOR THE PREPARATION OF SULFONYLUREA BASED COMPOUNDS
ABSTRACT
The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula...
ABSTRACT
SOLID FORM OF CENTANAFADINE AND PROCESS FOR PREPARATION THEREOF
The present invention relates to a crystalline form of centanafadine free base and eutectic mixture of centanafadine hydrochloride, compound of Formula I with co-former and process for preparation thereof. The present invention also relat...
The present invention provides a provides a pharmaceutical composition for inhalation comprising at least one long acting muscarinic antagonist, at least one long-acting ß-adrenoceptor agonist and one or more pharmaceutically acceptable excipients. The invention also provides the process of preparing pharmaceutical ...
“Improved Process For The Preparation Of 3 Oxo 3,4 Dihydro 2 H Benzo[B][1,4]Thiazine 6 Carbaldehyde”
ABSTRACT
“IMPROVED PROCESS FOR THE PREPARATION OF 3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]THIAZINE-6-CARBALDEHYDE”
Present invention provides an improved process for the preparation of 3-Oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbaldehyde. The present invention also provides novel intermediate and its use for the ...
ABSTRACT
A PROCESS FOR THE PREPARATION OF DEUCRAVACITINIB AND A NOVEL INTERMEDIATE THEREOF
The present invention relates to a process for the preparation of deucravacitinib, or a pharmaceutically acceptable salt, or a solvate thereof. Further, the present invention relates to a novel intermediate compound and proc...
Present invention relates to topical pharmaceutical composition of suitable HIF prolyl hydroxylase inhibitors. Preferably, present invention is about the topical pharmaceutical composition of compound of formula (Ia). Disclosed topical pharmaceutical composition comprises compound of formula (Ia) or its pharmaceutic...
ABSTRACT
ANTHRAQUINONE DERIVATIVES TO TREAT CYTOKINE-RELATED DISORDERS
The invention provides compounds of the general formula (I) having the potential to treat cytokine-related disorders especially osteoarthritis, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceut...
The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions conta...
Present invention relates to development of compound of formula (Ia) for treatment of sickle cell anaemia. Invention also relates to the pharmaceutical composition comprising compound of formula (Ia) or its pharmaceutically acceptable salts for treatment of sickle cell anaemia.
The present invention relates to novel crystalline forms of a quinolone compound of Formula (I). The invention also relates to processes for the preparation crystalline forms of the compound of Formula (I). Further the disclosure provides a process for the preparation of compound of Formula (I), intermediates, impur...
ABSTRACT
A GREEN PROCESS FOR THE PREPARATION OF CRYSTALLINE DESIDUSTAT
The present invention relates to a field of pharmaceuticals, in particular to an improved process for the preparation of a crystalline form of desidustat substantially free from other crystalline forms. The process can provide the crystalline...
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF SITAGLIPTIN FREE FROM GENOTOXIC IMPURITIES
The present invention relates to sitagliptin or a pharmaceutically acceptable salt thereof substantially free from genotoxic impurities particularly nitrosamine impurities and processes for its preparation. In particular...
Process of purifying anti-CD38 antibody
Abstract
The present invention provides process of purification of anti-CD38 antibody, preferably, daratumumab comprises affinity chromatography followed by cation exchange chromatography followed by mixed mode chromatography. Aspects of the present invention further compr...
The invention relates to once a day pharmaceutical compositions comprising a fixed dose combination of a ?? blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or ester thereof with one or more pharmaceutically acceptable excipients. In addition...
The present invention relates to the development of therapeutic compound for the treatment of glomerular diseases. Specifically, present invention relates to use of compound of formula (Ia) or its pharmaceutically acceptable salt or combination thereof or pharmaceutical composition thereof for the treatment of glome...
The present invention relates to novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures, their optically active forms and their use in the treatment of inflammatory conditions such as psor...
ABSTRCT
“NEW PROCESS FOR PREPARATION OF AFICAMTEN”
The present invention relates to a new process for preparation of Aficamten. The present invention also relates to a novel intermediate compound or a salt, isomer or mixture thereof. Further, the present invention relates to a process for preparation of novel in...
A combination of vaccine formulation against human papillomavirus and hepatitis E virus infection
Abstract
Present invention provides a vaccine formulation comprising of human papillomavirus (HPV) virus like particles (VLPs) in combination with hepatitis E virus antigen (HEV) and suitable excipients. Preferred h...
ABSTRACT
AMORPHOUS FORM OF RESMETIROM AND PROCESS FOR PREPARATION THEREOF
The present invention relates to an amorphous form of resmetirom. In particular, the present invention relates to an amorphous solid dispersion of resmetirom. The present invention relates to processes for the preparation of amorphous form...
ABSTRACT
A PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF DEUCRAVACITINIB
The present invention relates to an improved process for the preparation of a crystalline form of deucravacitinib. The process provides the crystalline form of deucravacitinib on consistent basis with a high purity and substantially fr...
ABSTRACT
COMPOSITION COMPRISING HIGH PURITY DEUCRAVACITINIB AND METHOD FOR PREPARATION THEREOF
The present invention relates to high purity deucravacitinib, compositions and process for the preparation thereof. In particular, the present invention relates to compositions comprising deucravacitinib having a purit...
ABSTRACT
ORAL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF AZATHIOPRINE
The present invention relates to oral modified release pharmaceutical compositions of azathioprine comprising plurality of delayed release azathioprine particles, and at least one pharmaceutically acceptable excipient. Further, the modifi...
ABSTRACT
PROCESSES FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES
The present invention relates to mirabegron substantially free from genotoxic impurities particularly nitrosamine impurities of Formula (I), (II), (III), (IV), (V) and processes for its preparation. In particular, the invention r...
ABSTRACT
“AN IMPROVED PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF A TRIAMINOPYRIMIDINE COMPOUND”
The present invention relates to a field of pharmaceuticals, in particular to an improved process for the preparation of a crystalline form of triaminopyrimidine compound of Formula I as described herein. ...
The invention provides compounds which are active to control IL17A mediated pathways and their use for the treatment of inflammatory diseases. The novel compounds are defined by the general formula (1) as given below. The compounds of the present invention are useful in the treatment of the human or animal body. The...
The aim of the invention is to provide liquid composition of Semaglutide with phenol in concentration of 0.11% w/w to 0.5% w/w which will enhance stability of the composition. Also provided herein a process for the preparation of composition of Semaglutide and method of using the same for treating diabetes and obesi...
The present invention relates to lyophilized pharmaceutical compositions of copper histidinate and one or more pharmaceutically acceptable excipients. It also relates to processes for preparing such compositions.
The present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA). The invention also describes the preparation of such combination and its compositions.
The present invention provides novel compounds of Formula (I) or its pharmaceutically acceptable salts. The novel compounds reported in present invention are suitable for the treatment against infection caused by Gram-positive bacteria.
The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula (I-a). Present invention also provides some novel impurities generated during pr...
ABSTRACT
A PROCESS FOR THE PREPARATION OF A TRIAMINOPYRIMIDINE COMPOUND AND NOVEL INTERMEDIATES THEREOF
The present invention relates to a process for the preparation of a triaminopyrimidine compound of Formula I. Further, the present invention relates to the novel intermediate compounds and process for preparat...
The present invention describes a combination of clobetasol and hyaluronate with an average molecular weight of between 40 and 60 kDa for the treatment of Psoriasis. The formulation is preferably in a topical form. The topical pharmaceutical composition comprises, a therapeutically effective amount of 0.01 to 0.05% ...
The present invention relates to FcRn-antagonist or Fc variant(s) protein and preparation thereof. Said Fc variant(s) has altered binding affinity towards FcRn. In one aspect, the Fc variant(s) according to the present invention comprises L234A, L235A, T307N, V308P, L309Y, P329G, H433R, N434W amino acid substitution...
The present invention provides novel stable pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab formulated in presence of arginine containing buffer(s), wherein the arginine containing buffer is selected from arginine-succinate buffer, arginine-phosphate buffer arginine-acetate buffer, arginine-a...
ABSTRACT
PROCESS FOR THE PREPARATION OF DARUNAVIR
A process for the preparation of darunavir comprises the reacting of 4-amino-N-(2R,3S) (3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-benzenesulfonamide with 2,5-dioxopyrrolidin-1-yl((3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl) carbonate in N,N-dimethyl formamide (...
ABSTRACT
A PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE PREPARATION OF A TRIAMINOPYRIMIDINE COMPOUND
The present invention relates to a process for the preparation of intermediates for the preparation of a triaminopyrimidine compound. Particularly, the invention relates to an improved process for the pr...
The present invention provides method of preparing brentuximab vedotin with purity of more than 97 % comprising reduction and conjugation of brentuximab with mc-vc-PABC-MMAE in a suitable buffer and at a suitable pH in which brentuximab antibody was kept. The present invention provides method of purifying brentuxi...
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparation
[Class : 5] Medicinal And Pharmaceutical Preparation
[Class : 5] Medicinal And Pharmaceutical Preparation
View +168 more Brands for Zydus Lifesciences Limited.
Charges
28 May 2014
The Bank Of Tokyo Mitsubishi Ufj Limited
120 Crore
21 December 2012
Bank Of Baroda
1,450 Crore
24 December 2015
Citi Bank N.a.
225 Crore
07 August 2014
Citi Bank N.a.
93 Crore
31 May 2013
The Bank Of Tokyo-mitsubishi Ufj Ltd
112 Crore
10 October 2013
Barclays Bank Plc
130 Crore
24 January 2012
The Bank Of Nova Scotia Asia Limited
102 Crore
21 November 2013
Citi Bank N.a.
94 Crore
12 December 2011
Bank Of America N.a.
38 Crore
19 February 2010
Idbi Trusteeship Services Limited
50 Crore
21 September 2011
Idbi Trusteeship Services Limited
175 Crore
12 January 2012
Dbs Bank Ltd
77 Crore
28 April 2009
Hdfc Bank Limited
75 Crore
17 May 2012
The Bank Of Tokyo- Mitsubishi Ufj Ltd
34 Crore
28 December 2004
Icici Bank Limited
13 Crore
19 July 2007
Idbi Bank Limited
8 Crore
30 November 2010
Bank Of Baroda (security Trustee)
69 Crore
11 September 2008
Calyon
123 Crore
20 June 2007
Citi Bank N.a.
42 Crore
18 March 2008
Bank Of Baroda
650 Crore
29 June 2010
Standard Chartered Bank (security Agent)
46 Crore
07 September 2009
Standard Chartered Bank (security Agent)
48 Crore
10 April 2009
Bank Of Baroda (security Trustee)
41 Crore
27 July 2007
Bnp Paribas
54 Crore
31 March 2006
Bnp Paribas
40 Crore
30 May 2007
Icici Bank Limited
29 Crore
11 January 2005
Icici Bank Limited
46 Crore
09 December 2002
Idbi Bank Limited
2 Crore
11 January 2005
Bnp Paribas India As Agent Of Bnp Paribas Singapore
28 Crore
20 June 2005
The Saraswat Co-operative Bank Limited
2 Crore
23 October 2000
The Saraswat Co-op. Bank Ltd.
3 Lak
23 November 2005
The Saraswat Co-op Bank Ltd
15 Lak
11 January 2001
Bank Of Baroda
20 Crore
19 January 2006
State Bank Of India
44 Crore
16 June 1983
Bank Of Maharashtra
2 Lak
21 October 1997
Bank Of Maharashtra
60 Lak
30 December 1983
Bank Of Maharashtra
4 Lak
04 July 1996
Bank Of Maharashtra
25 Lak
09 February 1987
Bank Of Maharashtra
13 Lak
30 August 1984
Bank Of Maharashtra
7 Lak
24 June 2002
Bank Of Maharashtra
33 Lak
04 December 1986
Bank Of Maharashtra
9 Lak
21 November 2002
Bank Of Maharashtra
1 Crore
21 September 1991
Bank Of Maharashtra
18 Lak
09 June 1987
Bank Of Maharashtra
13 Lak
13 February 2001
Bank Of Maharashtra
43 Lak
17 February 2004
Bank Of Baroda
45 Crore
03 June 1999
Bank Of Baroda With Sbs Corporation Bank Global Trust Bank Ltd
166 Crore
20 June 2005
The Saraswat Co-operative Bank Limited
7 Crore
30 August 2003
Il & Fs Trust Company Limited
60 Crore
14 February 2001
Icici Bank Ltd.
60 Crore
23 February 2004
Bnp Paridasindiaasagentofbnpparibassingapore
18 Crore
31 July 2002
Icici Bank Ltd
0
06 August 1999
Bank Of Maharashtra
2 Crore
10 September 1999
The Saraswat Co-op. Bank Ltd.
4 Lak
19 April 1997
The Saraswat Co-op. Bank Ltd.
3 Lak
18 October 1997
The Saraswat Co-op. Bank Ltd.
2 Lak
21 April 1995
Bank Of Maharashtra
21 Lak
26 November 1992
The Maharashtra State Financial Corporation
75 Lak
23 December 1992
The Saraswat Co-op. Bank Ltd.
1 Lak
21 December 2012
Others
0
21 November 2013
Citi Bank N.a.
0
27 July 2007
Bnp Paribas
0
30 May 2007
Icici Bank Limited
0
20 June 2007
Citi Bank N.a.
0
26 November 1992
The Maharashtra State Financial Corporation
0
13 February 2001
Bank Of Maharashtra
0
18 October 1997
The Saraswat Co-op. Bank Ltd.
0
23 December 1992
The Saraswat Co-op. Bank Ltd.
0
21 September 1991
Bank Of Maharashtra
0
09 June 1987
Bank Of Maharashtra
0
28 December 2004
Icici Bank Limited
0
31 July 2002
Icici Bank Ltd
0
09 December 2002
Idbi Bank Limited
0
11 January 2005
Icici Bank Limited
0
31 March 2006
Bnp Paribas
0
17 February 2004
Bank Of Baroda
0
21 November 2002
Bank Of Maharashtra
0
30 August 2003
Il & Fs Trust Company Limited
0
14 February 2001
Icici Bank Ltd.
0
23 February 2004
Bnp Paridasindiaasagentofbnpparibassingapore
0
07 August 2014
Citi Bank N.a.
0
28 May 2014
Others
0
10 October 2013
Barclays Bank Plc
0
24 January 2012
The Bank Of Nova Scotia Asia Limited
0
21 September 2011
Idbi Trusteeship Services Limited
0
30 November 2010
Bank Of Baroda (security Trustee)
0
19 February 2010
Idbi Trusteeship Services Limited
0
07 September 2009
Standard Chartered Bank (security Agent)
0
28 April 2009
Hdfc Bank Limited
0
10 April 2009
Bank Of Baroda (security Trustee)
0
03 June 1999
Bank Of Baroda With Sbs Corporation Bank Global Trust Bank Ltd
0
18 March 2008
Bank Of Baroda
0
23 October 2000
The Saraswat Co-op. Bank Ltd.
0
20 June 2005
The Saraswat Co-operative Bank Limited
0
20 June 2005
The Saraswat Co-operative Bank Limited
0
10 September 1999
The Saraswat Co-op. Bank Ltd.
0
11 January 2005
Bnp Paribas India As Agent Of Bnp Paribas Singapore
0
09 February 1987
Bank Of Maharashtra
0
04 December 1986
Bank Of Maharashtra
0
24 December 2015
Citi Bank N.a.
0
30 August 1984
Bank Of Maharashtra
0
30 December 1983
Bank Of Maharashtra
0
23 November 2005
The Saraswat Co-op Bank Ltd
0
16 June 1983
Bank Of Maharashtra
0
31 May 2013
The Bank Of Tokyo-mitsubishi Ufj Ltd
0
19 July 2007
Idbi Bank Limited
0
17 May 2012
The Bank Of Tokyo- Mitsubishi Ufj Ltd
0
11 January 2001
Bank Of Baroda
0
12 January 2012
Dbs Bank Ltd
0
12 December 2011
Bank Of America N.a.
0
06 August 1999
Bank Of Maharashtra
0
21 October 1997
Bank Of Maharashtra
0
29 June 2010
Standard Chartered Bank (security Agent)
0
24 June 2002
Bank Of Maharashtra
0
19 April 1997
The Saraswat Co-op. Bank Ltd.
0
19 January 2006
State Bank Of India
0
21 April 1995
Bank Of Maharashtra
0
11 September 2008
Calyon
0
04 July 1996
Bank Of Maharashtra
0
21 December 2012
Others
0
21 November 2013
Citi Bank N.a.
0
27 July 2007
Bnp Paribas
0
30 May 2007
Icici Bank Limited
0
20 June 2007
Citi Bank N.a.
0
26 November 1992
The Maharashtra State Financial Corporation
0
13 February 2001
Bank Of Maharashtra
0
18 October 1997
The Saraswat Co-op. Bank Ltd.
0
23 December 1992
The Saraswat Co-op. Bank Ltd.
0
21 September 1991
Bank Of Maharashtra
0
09 June 1987
Bank Of Maharashtra
0
28 December 2004
Icici Bank Limited
0
31 July 2002
Icici Bank Ltd
0
09 December 2002
Idbi Bank Limited
0
11 January 2005
Icici Bank Limited
0
31 March 2006
Bnp Paribas
0
17 February 2004
Bank Of Baroda
0
21 November 2002
Bank Of Maharashtra
0
30 August 2003
Il & Fs Trust Company Limited
0
14 February 2001
Icici Bank Ltd.
0
23 February 2004
Bnp Paridasindiaasagentofbnpparibassingapore
0
07 August 2014
Citi Bank N.a.
0
28 May 2014
Others
0
10 October 2013
Barclays Bank Plc
0
24 January 2012
The Bank Of Nova Scotia Asia Limited
0
21 September 2011
Idbi Trusteeship Services Limited
0
30 November 2010
Bank Of Baroda (security Trustee)
0
19 February 2010
Idbi Trusteeship Services Limited
0
07 September 2009
Standard Chartered Bank (security Agent)
0
28 April 2009
Hdfc Bank Limited
0
10 April 2009
Bank Of Baroda (security Trustee)
0
03 June 1999
Bank Of Baroda With Sbs Corporation Bank Global Trust Bank Ltd
0
18 March 2008
Bank Of Baroda
0
23 October 2000
The Saraswat Co-op. Bank Ltd.
0
20 June 2005
The Saraswat Co-operative Bank Limited
0
20 June 2005
The Saraswat Co-operative Bank Limited
0
10 September 1999
The Saraswat Co-op. Bank Ltd.
0
11 January 2005
Bnp Paribas India As Agent Of Bnp Paribas Singapore
0
09 February 1987
Bank Of Maharashtra
0
04 December 1986
Bank Of Maharashtra
0
24 December 2015
Citi Bank N.a.
0
30 August 1984
Bank Of Maharashtra
0
30 December 1983
Bank Of Maharashtra
0
23 November 2005
The Saraswat Co-op Bank Ltd
0
16 June 1983
Bank Of Maharashtra
0
31 May 2013
The Bank Of Tokyo-mitsubishi Ufj Ltd
0
19 July 2007
Idbi Bank Limited
0
17 May 2012
The Bank Of Tokyo- Mitsubishi Ufj Ltd
0
11 January 2001
Bank Of Baroda
0
12 January 2012
Dbs Bank Ltd
0
12 December 2011
Bank Of America N.a.
0
06 August 1999
Bank Of Maharashtra
0
21 October 1997
Bank Of Maharashtra
0
29 June 2010
Standard Chartered Bank (security Agent)
0
24 June 2002
Bank Of Maharashtra
0
19 April 1997
The Saraswat Co-op. Bank Ltd.
0
19 January 2006
State Bank Of India
0
21 April 1995
Bank Of Maharashtra
0
11 September 2008
Calyon
0
04 July 1996
Bank Of Maharashtra
0
Documents
Form INC-28-29102021-signed
Form MGT-14-05032021_signed
Letter of the charge holder stating that the amount has been satisfied-22122020
Form CHG-4-22122020_signed
CERTIFICATE OF SATISFACTION OF CHARGE-20201222
Listofshareholders31032020_R68531771_UPENSHAH_20201027124608.xlsx
Copy of MGT-8-24102020
Optional Attachment-(1)-24102020
Optional Attachment-(2)-24102020
Optional Attachment-(3)-24102020
Form MGT-7-24102020_signed
Form MSME FORM I-22102020_signed
Form MGT-14-14102020_signed
Copy of agreement-14102020
Optional Attachment-(1)-14102020
Form AOC-4(XBRL)-30092020_signed
Optional Attachment-(1)-25092020
Form MGT-15-09092020_signed
Optional Attachment-(1)-09092020
Form DPT-3-15082020-signed
Optional Attachment-(1)-13082020
Optional Attachment-(3)-13082020
Optional Attachment-(2)-13082020
Form MR-1-13072020_signed
Copy of shareholders resolution-13072020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -13072020
Optional Attachment-(1)-29062020
Optional Attachment-(1)-02042020
Optional Attachment-(2)-02042020
Copy of court order or NCLT or CLB or order by any other competent authority.-02042020
